KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $2.5 billion.

  • Royalty Pharma's Capital Expenditures fell 19.48% to $961.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 51.50%. This contributed to the annual value of $2.5 billion for FY2024, which is 18.44% up from last year.
  • Per Royalty Pharma's latest filing, its Capital Expenditures stood at $2.5 billion for FY2024, which was up 18.44% from $2.1 billion recorded in FY2023.
  • Royalty Pharma's 5-year Capital Expenditures high stood at $2.5 billion for FY2024, and its period low was $1.7 billion during FY2022.
  • Moreover, its 3-year median value for Capital Expenditures was $2.1 billion (2023), whereas its average is $2.1 billion.
  • As far as peak fluctuations go, Royalty Pharma's Capital Expenditures climbed by 26.78% in 2020, and later decreased by 20.53% in 2022.
  • Yearly analysis of 5 years shows Royalty Pharma's Capital Expenditures stood at $2.2 billion in 2020, then climbed by 0.42% to $2.2 billion in 2021, then declined by 20.53% to $1.7 billion in 2022, then climbed by 21.47% to $2.1 billion in 2023, then climbed by 18.44% to $2.5 billion in 2024.